JaxBio aims to change the way cancer is diagnosed and managed, with a simple and sensitive blood test. This test will enable early detection, monitoring of disease status, and predicting response to therapy.
The company has developed an ultra-sensitive method to detect genetic and epigenetic profiles in cell-free DNA, that occur during cancer initiation and progression. It extracts cell-free DNA from a blood sample and fluorescently label markers utilizing a proprietary process. The DNA is hybridized onto a custom chip, and each cancer type presents a unique pixel pattern signature that may be used for classifying the type and stage of the disease.

JaxBio is currently focused on developing its first diagnostic tests for lung cancer and hematological malignancies.